Inari Medical

The VIAFORT trial, the first prospective study to include inferior vena cava, iliac, and femoral veins, enrolled 89 patients with thrombotic disease and achieved an 83.4% primary patency rate at 12 months.

Stryker's newly launched Artix Thrombectomy System combines mechanical thrombectomy and aspiration capabilities, offering a novel solution for treating arterial blood clots in peripheral vessels.

• Large-bore mechanical thrombectomy demonstrates superiority over catheter-directed thrombolysis in acute intermediate-risk pulmonary embolism, reducing clinical deterioration and ICU stays. • Percutaneous transmural arterial bypass shows sustained patency at 3 years for complex superficial femoropopliteal lesions, offering a bypass alternative without open surgery. • The FDA approved a bioresorbable scaffold for below-the-knee infrapopliteal disease, showing safety and efficacy at 1 year compared to angioplasty alone.

The PROMISE II trial demonstrates sustained limb salvage and wound healing at 2 years using the LimFlow System for no-option CLTI patients.

The PROMISE II trial demonstrates sustained limb salvage and wound healing at two years using the LimFlow System for no-option CLTI patients.

• The Esprit BTK scaffold demonstrated superior long-term outcomes in treating chronic limb-threatening ischemia compared to percutaneous transluminal angioplasty. • Shockwave Javelin Peripheral IVL catheter met efficacy and safety goals, significantly reducing stenosis in severely calcified lesions. • TCAR using the ENROUTE system proves safe and effective for carotid stenosis in standard-surgical-risk patients, with low stroke and cranial nerve injury rates.

• The Esprit BTK scaffold demonstrated superior long-term outcomes compared to PTA in treating chronic limb-threatening ischemia, with a 61.5% limb salvage and primary patency rate at 2 years. • The Shockwave Javelin Peripheral IVL catheter met efficacy and safety goals, achieving a 99% effectiveness rate and 1.1% major adverse event rate at 30 days in treating calcified lesions. • Computer-assisted vacuum thrombectomy (CAVT) for intermediate-risk pulmonary embolism significantly reduced hospital length of stay and complications compared to other treatments. • Mechanical thrombectomy with the ClotTriever System for DVT showed significant symptom relief and improved vessel function, with 81.5% of limbs showing no postthrombotic syndrome at 2 years.

Edwards Lifesciences' tricuspid valve replacement device met its primary endpoint in a trial, showing improvement in patient-reported quality of life but no significant mortality benefit at 12 months.

The PEERLESS trial demonstrated that Inari Medical's FlowTriever system significantly reduced clinical deterioration and therapy escalation compared to catheter-directed thrombolytics (CDT) in intermediate-risk pulmonary embolism (PE) patients.

• The FDA granted traditional approval to Sirturo (bedaquiline) for treating rifampin- and isoniazid-resistant tuberculosis in adults and children, based on Phase 3 STREAM study data. • mResvia, an mRNA-based vaccine, received FDA approval for preventing lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults aged 60 years and older. • Capvaxive, a pneumococcal 21-valent conjugate vaccine, was approved for preventing invasive disease and pneumonia caused by Streptococcus pneumoniae in adults 18 years and older. • Several critical care medical devices, including infusion pumps and chest compression devices, were recalled due to potential for serious adverse health consequences.